Grifols outlines long-term plasma strategy, shares on Madrid in health sector spotlight

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 09:16.

Grifols (ES0171996087) positions itself as a long-term plasma-derived biopharmaceutical group with a focus on chronic conditions and critical care therapies. The Barcelona-based company is listed on Bolsa de Madrid, giving international investors access via the IBEX 35 benchmark index.

How Grifols builds its business

Grifols derives a significant portion of its revenue from plasma-derived medicines used in immunology, neurology and hematology, where patients often require lifelong treatment plans. The group operates hundreds of plasma donation centers globally, particularly in the United States, which secure the raw material for its fractionation plants and manufacturing network.

Plasma fractionation allows Grifols to separate key proteins such as immunoglobulins, albumin and clotting factors, which are then processed into therapies for conditions like primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy and liver disease. This vertically integrated chain from donor to finished product is central to the firm’s long-term economic moat, as described in its investor materials.

Strategic focus and sector peers

In the global plasma and specialty-biopharma space, Grifols competes with companies such as CSL, Takeda and Octapharma, which also operate large donor networks and offer similar immunoglobulin portfolios. The Spanish group emphasizes capacity expansion and efficiency in plasma collection as a way to support growth and maintain its positioning within the IBEX 35 health-care cohort.

Analyst coverage from major houses including UBS and Morgan Stanley tracks Grifols’ leverage trends, earnings trajectory and margin targets, often comparing its performance to broader European pharma benchmarks. According to recent consensus data compiled by MarketScreener, the majority of analysts rate the shares Neutral to Buy, with a wide range of target prices reflecting differing views on execution and debt reduction.

The therapies behind the stock

Grifols’ core business revolves around producing immunoglobulin therapies, such as Flebogamma and Gamunex, for patients with primary and secondary immunodeficiencies. The company also manufactures albumin products used in intensive care and liver disease, as well as specialty proteins for hematology and neurology indications.

Where the stock trades today

The Grifols shares (ES0171996087) trade on Bolsa de Madrid under the ticker GRF, quoted in euros. As of 2026-06-26, 17:35, the stock closed at 9.50 euros on the Spanish exchange.

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any form of financial promotion. All data are based on sources believed to be reliable but cannot be guaranteed; investors should conduct their own research or consult a licensed advisor before making investment decisions.